Toxicology, Pathology and Biodistribution Core (TPB Core)

毒理学、病理学和生物分布核心将提供mNPs在所有主要器官组织以及特定环境下单个细胞中的运动和沉积的定性和定量评估。TPB核心还将提供专门和全面的药代动力学（Lewis）、人类和动物病理学/病理生理学（Memoli和Hoopes）和TEM/SEM （Daghlian）专业知识，以研究mNPs（铁、涂层、靶向肽、荧光探针等）和/或交变磁场（AMF）暴露导致的潜在细胞和/或组织变化。由于整个DCCNE应用的主要目标是优化观察和选择性地将mNP/铁递送到癌细胞以进行随后的细胞毒性激发的方法，因此评估和定量细胞和组织中的铁水平（普鲁士蓝组织形态测定法和ICP-MS）以及由此产生的肿瘤和正常组织中的病理效应至关重要。

The Toxicology, Pathology, and Biodistribution Core will provide qualitative and quantitative assessment of the movement and deposition of mNPs in all major organ tissues as well as individual cells in specific settings. The TPB core will also provide dedicated and comprehensive pharmacokinetic (Lewis), human and animal pathology/pathophysiology (Memoli and Hoopes) and TEM/SEM (Daghlian) expertise for potential cellular and/or tissue change resulting from the mNPs (iron, coatings, targeting peptides, fluorescent probes etc and/or the alternating magnetic field (AMF) exposure. Since it is the primary goal of the entire DCCNE application to optimize methods for the observation and selectively delivery of mNP/lron to cancer cells for subsequent cytotoxic excitation, the assessment and quantification of iron levels in cells and tissues (Prussian Blue histomorphometry and ICP-MS) and the resultant pathologic effects in the tumor and normal tissues, is of paramount importance. The TPB Core will be a central participant in the determination ofthe relative ability ofthe various NP physical parameters, coatings, internalizing vs noninternalizing ScFv peptides to selectively target mNP /iron to cancer cells in vitro and in vivo (Project 1). In addition, TEM will allow an accurate assessment of the volume and anatomic location of the various NPs with respect to effective excitation and cytotoxicity. TPB assessments will determine which peptides have the most targeting promise for future use in preclinical in vivo ovarian and breast tumor models (Projects 2 and 3). In Project 2, the TPB will play an essential role determining the accuracy and sensitivity ofthe mNP in vivo imaging techniques. Pathologic co-registration and validation of changes observed by noninvasive imaging techniques such as optical spectroscopy and MRI remains the gold standard for determining the sensitivity and reliability of new imaging techniques. In Project 3, the use of ICP-MS and Prussian Blue histomorphometry mNP /iron quantification techniques will allow investigators to determine the absolute role of mNP/lron content in tumor treatment efficacy studies. In Project 4, the TPB Core will be important in determining the level of iron that is taken up by the ovarian cancer dendritic cells, cancer cells and other abdominal tissues that are exposed to the ip delivered mNPs. Since the targeted NP exposure field, in this cancer model, is large, there Is a risk of normal tissue injury. Pathologic assessment of these mice will be extremely important for safety and the understanding of toxicity/efficacy.